Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TILT-123 |
| Trade Name | |
| Synonyms | igrelimogene litadenorepvec|TILT 123|TILT123 |
| Drug Descriptions |
TILT-123 is an oncolytic adenovirus engineered to express cytokines TNF-alpha and IL-2, potentially leading to activation of the immune response, and inhibition of tumor growth when combined with immune checkpoint inhibitors (PMID: 33513935). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C175454 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Avelumab + TILT-123 | Avelumab TILT-123 | 0 | 1 |
| Pegylated liposomal doxorubicin + Pembrolizumab + TILT-123 | Pegylated liposomal doxorubicin Pembrolizumab TILT-123 | 0 | 1 |
| Pembrolizumab + TILT-123 | Pembrolizumab TILT-123 | 0 | 2 |
| TILT-123 | TILT-123 | 0 | 3 |